# New Leaf Venture Partners

New Leaf Venture Partners is a Venture Capital based in New York, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, United States
- **Founded:** 2005
- **Assets under management:** Undisclosed
- **Website:** nlvpartners.com
- **LinkedIn:** https://www.linkedin.com/company/new-leaf-venture-partners

## Regulatory record

- **CRD number:** 163897
- **SEC file number:** 801-80793
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/163897

## About

New Leaf Venture Partners is an SEC-registered investment adviser in NEW YORK, NY, registered since 2015. The firm manages approximately $408 million in regulatory assets. It has 4 employees and 2 investment advisers.

## Sectors

- Healthcare Services
- Digital Health
- AI/ML
- Enterprise Software

## People

- Ron Hunt — Team
- Vijay Lathi — Team
- Craig Slutzkin — Team

## Questions

### What investment stages does New Leaf Venture Partners target?

The firm invests from seed through late-stage expansion, and its mandate includes PIPE transactions, buyouts, recapitalizations, and spin-offs. Portfolio disclosures span early-stage therapeutics to growth-stage digital health infrastructure. The flexibility to move between private and public-company financing is a defining feature of its strategy.

### Which categories of healthcare does New Leaf pursue?

New Leaf pursues therapeutics for rare diseases, oncology, immunology, and cardiovascular conditions alongside diagnostics — including AI-driven imaging — and healthcare data infrastructure. Portfolio companies such as Cogent Biosciences and Sunbird Bio represent the therapeutic side, while Kalderos and BrightInsight address operational and compliance layers.

### Where does New Leaf deploy capital geographically?

The firm's portfolio reaches major US biotech hubs including Cambridge, South San Francisco, and Boulder, as well as international markets such as Denmark and Canada. While its own office is in New York, capital deployment follows scientific talent clusters rather than a single geography.

### What does New Leaf's exit track record look like?

New Leaf's portfolio history, as self-reported, includes 54 companies taken public and 44 acquired. Several current portfolio names trade on Nasdaq, including Cogent Biosciences and Rocket Pharma, while Dice Therapeutics was acquired by Eli Lilly. The dual exit path — IPO and strategic acquisition — is central to its healthcare thesis.

## Related profiles

- [New Layer Capital](https://altss.com/profile/new-layer-capital)
- [Newlin Ventures](https://altss.com/profile/newlin-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/new-leaf-venture-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology